Study identifies TAK1 gene as key brake for cancer immunotherapy

Australian researchers have found that the TAK1 gene helps cancer cells survive immune system attacks, uncovering a mechanism that might limit the effectiveness of immunotherapy treatments.

Cancer immunotherapies can work thoroughly, but in some cases they’re inadequate as a result of the survival processes built into tumors that help them resist immune system attacks.

Researchers from the Olivia Newton-John Cancer Research Institute (ONJCRI) and WEHI discovered that the TAK1 gene acts like a security switch, protecting cancer cells from the powerful signals generated by CD8⁺ T cells.

TAK1 was identified by conducting a big genetic screen to search for genes that help cancer cells survive attacks by CD8⁺ T cells, necessary killer cells in our immune system.

Dr. Anne Huber, postdoctoral researcher at ONJCRI, affiliated to La Trobe University because the School of Cancer Medicine, says:

The researchers tested the importance of the TAK1 gene in cancer cell survival by silencing it using CRISPR/Cas9 technology. In preclinical models with typical immune function, they found that tumors grow poorly without TAK1, showing that the immune system is best at controlling cancer cells.

Dr. Huber says:

By turning off TAK1, cancer cells could be eliminated way more easily by the immune system, giving hope for simpler treatment options in the long run.

Dr. Tirta (Moio) Daja, Possdator Reseas Resourker or ONJCRI, Soying:

In the long run, the team will conduct further research into blocking TAK1 using revolutionary liquid nanoparticle technology and testing the effectiveness of existing immunotherapies against cancer cells.

The research has predominantly been conducted on quite a lot of cancer types Melanomawhich is usually handled Immunotherapy It’s diagnosed in 330,000 people worldwide and causes 60,000 deaths annually (2022 data).

This work was carried out in collaboration with the laboratory of Dr. Stephin Vervoort and Sarahi Mendoza Rivera at WEHI.